90Y
WordNet
- a silvery metallic element that is common in rare-earth minerals; used in magnesium and aluminum alloys (同)Y, atomic number 39
PrepTutorEJDIC
- イットリウム(希土類元素;化学記号は Y)
Wikipedia preview
出典(authority):フリー百科事典『ウィキペディア(Wikipedia)』「2016/02/04 03:12:22」(JST)
[Wiki en表示]
Yttrium-90
Full table
|
General |
Name, symbol |
Yttrium-90,90Y |
Neutrons |
51 |
Protons |
39 |
Nuclide data |
Half-life |
64.1 h |
Yttrium-90, 90Y, is a medically significant isotope of yttrium.[1] Yttrium-90 has a wide and valuable use in radiation therapy to treat cancer.[2]
Contents
- 1 Decay
- 2 Production
- 3 See also
- 4 References
- 5 External links
DecayEdit
90Y undergoes β− decay to zirconium-90 with a half-life of 64.1 hours[3] and a decay energy of 2.28 MeV.[4] It also produces 0.01% 1.7 MeV[5] photons along the way. Interaction of the emitted electrons with matter can lead to Bremsstrahlung radiation.
ProductionEdit
Yttrium-90 is a decay product of strontium-90 which makes up about 5% of the nuclear daughter isotopes when uranium is fissioned.[6][not in citation given] Yttrium-90 is produced by chemical high-purity separation from strontium-90, a fission product of uranium in nuclear reactors.[7]
See alsoEdit
- Isotopes of yttrium
- Unsealed source radiotherapy
ReferencesEdit
- ^ Vincent T. DeVita; Theodore S. Lawrence; Steven A. Rosenberg; Robert A. Weinberg; Ronald A. DePinho (1 April 2008). DeVita, Hellman, and Rosenberg's cancer: principles & practice of oncology. Lippincott Williams & Wilkins. pp. 2507–. ISBN 978-0-7817-7207-5. Retrieved 9 June 2011.
- ^ Arkadiy Kheyfits (October 2010). "Yttrium-90 Radioembolization". Radiology Today. Retrieved 2012-10-23.
- ^ "Y-90 Handling Precautions" (PDF). Retrieved 2015-07-15.
- ^ "Table of Isotopes decay data". The Lund/LBNL Nuclear Data Search. February 1999. Retrieved 2012-10-23.
- ^ Rault, E.; Vandenberghe, S.; Staelens, S.; Lemahieu, I. (2009). Optimization of Yttrium-90 Bremsstrahlung Imaging with Monte Carlo Simulations. 4th European Conference of the International Federation for Medical and Biological Engineering. pp. 500–504. Retrieved 21 October 2013.
- ^ "Strontium | Radiation Protection | US EPA". EPA. 24 April 2012. Retrieved 2012-10-23.
- ^ "PNNL: Isotope Sciences Program - Yttrium-90 Production". PNNL date=February 2012. Retrieved 2012-10-23.
External linksEdit
Therapeutic radiopharmaceuticals (V10)
|
|
Pain palliation |
|
|
Adrenergic tumors |
|
|
CD20 antibodies |
|
|
Radionuclides |
alpha emitters
|
|
|
beta emitters
|
- 153Sm
- 90Y
- 32P
- 131I
- 89Sr
- 165Dy
- 169Er
- 186Re
- 198Au
|
|
|
Radiation oncology
- (ICD-9-CM V3 92.2-92.3
- ICD-10-PCS D)
|
|
Specific
therapies
|
Teletherapy1 |
by photon |
- Superficial X-rays
- Orthovoltage X-rays
- Megavoltage X-rays
- Radiosurgery / Stereotactic radiation therapy
- CHHIP
- Cobalt therapy
|
|
by electron |
|
|
by hadron |
- Particle therapy
- fast neutron
- neutron-capture
- proton
|
|
|
Brachytherapy2 |
- Prostate
- Plaque radiotherapy (125I)
- Selective internal radiation therapy / SIR-Spheres / TheraSphere (90Y)
|
|
Unsealed source
radiotherapy3
|
- Iobenguane (131I)
- 90Y
- Lexidronam (153Sm)
- 89Sr
- Radioimmunotherapy
|
|
Other |
- Intraoperative radiation therapy
- Tomotherapy
|
|
|
Conditions |
- Radiation burn
- Radiation proctitis
- Radiation-induced lung injury
|
|
Features and
equipment
|
- BEAMnrc
- Bolus
- Bragg peak
- D50
- Dose profile
- Dose verification system
- Dose-volume histogram
- Dosimetry
- Isocenter
- Mobetron
- Monitor unit
- Multileaf collimator
- Nanoimpellers
- Neutron generator
- Oxygen enhancement ratio
- Pencil
- Pencil-beam scanning
- Percentage depth dose curve
- Radiation oncologist
- Radiation treatment planning
- Radiopharmacology
- Tissue to Air Ratio (TAR)
|
|
- 1 Also known as external-beam radiotherapy.
- 2 Also known as sealed-source radiation therapy.
- 3 Also known as systemic radioisotope therapy.
|
|
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
Index of neoplasms and cancer
|
|
Description |
- Tumor suppressing and oncogenes
- Tumor markers
- Carcinogen
|
|
Disease |
- Neoplasms and cancer
- Symptoms and signs
- Paraneoplastic
|
|
Treatment |
- Radiotherapy
- Drugs
- Immunotherapy
- intracellular chemotherapeutics
- extracellular chemotherapeutics
- adjuvant detoxification
|
|
|
English Journal
Japanese Journal
- 日本における⁹⁰Y-イブリツモマブ・チウキセタンの適正使用
- Transarterial Y90 radioembolization versus chemoembolization for patients with hepatocellular carcinoma: A meta-analysis
- 化学リーチングによるレアアース泥からのレアアース回収方法の検討:–レアアース泥の開発と工学的利用に向けて–
Related Links
- 半減期 28.79年崩壊方式ベータ線を放出してイットリウム-90(90Y、64.00時間)となり、イットリウム-90もベータ崩壊してジルコニウム-90(90Zr)となる。イットリウム-90は、核分裂直後はほとんど存在しないが、時間の経過とともに量が増す。
- イットリウム( 90 Y)から放射されるβ線は、近傍の腫瘍細胞にも照射されるため、大きな腫瘍や血管分布の少ない腫瘍にもダメージを与えます。 ゼヴァリンインジウムで適格と診断された場合に用います。
- Yttrium-90 production. We are involved in the production of medical isotopes for medical devices used in radioembolization for a long time. Bot yttrium-90 and holmium-166 are part of NRG’s product portfolio. Our full-service approach includes preparing irradiation capsules, irradiation, waste handling and logistics.
★リンクテーブル★
[★]
- 英
- yttrium 90
- 同
- イットリウム90
- 関
- イットリウム
[★]
イットリウム
- 関
- Y